Loading...
•
Sep 30, 2025
Journey Medical Q3 2025 Earnings Report
Journey Medical reported a revenue increase in Q3 2025 driven by strong Emrosi performance, though the company posted a net loss.
Key Takeaways
Journey Medical achieved strong year-over-year revenue growth in Q3 2025, largely fueled by the launch and commercial momentum of Emrosi. Despite higher revenues and improving margins, the company reported a net loss of $2.3M.
Revenue rose to $17.6 million, up 21% YoY due to Emrosi sales
Emrosi generated $4.9 million in net revenue during Q3
Gross margin improved sequentially to 67.4%
Adjusted EBITDA reached $1.7 million, up from $0.3 million in Q3 2024
Revenue by Segment
Forward Guidance
No formal financial guidance was provided, but the company emphasized Emrosi’s growth trajectory and operational leverage potential.
Positive Outlook
- Strong launch and growth of Emrosi with 146% increase in prescriptions QoQ
- Gross margin expansion over consecutive quarters
- Adjusted EBITDA turned positive year-over-year
- Cash position increased to $24.9 million
- Over 100 million commercial lives now covered for Emrosi
Challenges Ahead
- Net loss of $2.3 million reported for the quarter
- Operating loss of $1.5 million despite revenue growth
- No forward-looking revenue or profit guidance provided
- SG&A expenses rose due to Emrosi commercialization
- Gross margin declined YoY due to one-time favorable items in prior year
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...